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http://dx.doi.org/10.1016/j.jmii.2012Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium
indologenes infections and antimicrobial susceptibilities of C indologenes.
Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at
a medical center, we analyzed the relationship between the prevalence of C indologenes
infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic
susceptibility, and outcomes.
Results: Colistin and tigecycline were introduced into clinical use at this medical center since
August 2006. The increasing numbers of patients with C indologenes pneumonia and bacter-
emia correlated to increased consumption of colistin (p Z 0.018) or tigecycline
(p Z 0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate
was 63.6% and 35.2% (p Z 0.015), respectively. Administration of appropriate antibiotics
showed significant benefit in 14-day survival in patients with C indologenes bloodstream infec-
tion (p Z 0.040). In bacteremic patients, old cardiovascular accident (p Z 0.036) and cancer
(p Z 0.014) were the most common comorbidity. The most common co-infection pathogen in
patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed
by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91,
24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of theus Disease Society of Taiwan, Annual conference, 2012.
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426 F.-L. Chen et al.215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (suscepti-
bility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%).
Conclusion: The present study showed a trend of increasing prevalence of C indologenes infec-
tion after introduction of colistin and tigecycline usage. The bacteremia group had higher
mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam,
ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis.
Trimethoprim-sulfamethoxazole was a potential antimicrobial agent in vitro for C indologenes.
To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Chryseobacterium indologenes, formerly known as Fla-
vobacterium indologenes, or Flavobacterium aureum,
belongs to CDC group IIb. It is non-motile, catalase-positive,
oxidase-positive, indole-positive, non-glucose-fermenting
Gram-negative bacilli. C indologenes is a rare pathogen in
humans and is not normally present in the human microflora
although it iswidely distributed innature.1C indologenes can
cause various types infections, such as bacteremia, pneu-
monia, meningitis, and artificial shunt infection,2e7 espe-
cially in thosewhoarehospitalizedwith long-term indwelling
devices and prolonged exposure to broad-spectrum antibi-
otics. With increasing clinical usage of colistin and tigecy-
cline against emerging carbapenem-resistant pathogens,
such as Acinetobacter baumannii, extended-spectrum b-
lactamases-producing Escherichia coli and Klebsiella pneu-
moniae, Chryseobacterium species have caused significant
problems in critical healthcare setting.8,9 At present, even
with the increasing incidence of healthcare-associated
infections due to Chryseobacterium species other than
Cmeningosepticum,1 there is no “gold standard” or guideline
formanagement ofC indologenes infection. Vancomycin and
aminoglycoside are not effective against C indologenes.1,10
C indologenes is also intrinsically resistant to carbapenems
and cephalosporins due to its production ofmolecular class A
b-lactamase11 and class B carbapenem-hydrolyzing b-lacta-
mase (IND1eIND7).12e15 Susceptibility data to tigecycline,
a glycylcycline antibiotic, structurally similar to the mino-
cycline, remain limited.
In this retrospective study, we investigated the trend in
C indologenes infection after clinical usage of colistin and
tigecycline. We also analyzed the clinical manifestations
and microbiological characteristics of C indologenes
infections.
Materials and methods
Clinical data collection
We isolated and identified C indologenes isolates from
clinical samples, such as bloodstream, central venous
catheter (CVC) tip, sputum, wound culture, urine culture,
and other aseptic body fluid, between January 1, 2004 and
September 30, 2011, at a 732-bed medical center in
northern Taiwan. The sputum isolates obtained from
a patient with new-onset pneumonia within 14 days and
bacteremic isolates from a patient with new-onsetbacteremia within 7 days were thought as the same
strains and thus excluded.
We retrospectively reviewed the medical records of
patients from whose samples C indologenes had been iso-
lated. Data on underlying diseases, initial admission diag-
nosis, the use of indwelling catheters, ventilator,
hemodialysis, administration of chemotherapy, infectious
complication, and clinical outcome were recorded.
Microbiology
We examined all positive cultures following Gram staining
and subcultured them on blood agar plates and eosine
methylene blue agar plates for further identification. The
Becton Dickinson Phoenix Automated Microbiology System
was used to identify the bacterial species according to the
manufacturer’s instructions. All isolates of C indologenes,
Flavobacterium indologenes, or Flavobacterium aureum
were included in the study. Only the blood isolates were
stored at 70C in a refrigerator and subcultured twice
before further studies.
The minimal inhibitory concentration (MIC) values
of cefotaxime, ceftazidime, cefepime, piperacillin-
tazobactam, aztreonam, imipenem, meropenem,
gentamicin, amikacin, ciprofloxacin, levofloxacin, chloram-
phenicol, trimethoprim-sulfamethoxazole (TMP-SMZ), and
colistin were determined using the Becton Dickinson
Phoenix Automated Microbiology System following the
manufacturer’s instructions. Susceptibility to cefoperazone-
sulbactam and tigecycline was determined using the agar
diffusion disk. An inhibition zone of more than 21mm around
a 75e35 mg cefoperazone-sulbactam disk or more than
19 mm by a 15 mg tigecycline disk (the criteria recommended
by the U.S. Food and Drug Administration for Enter-
obacteriaceae) was regarded as susceptible. The MIC values
of tigecycline for bacteremic isolates were determined using
the E-test, and the susceptibility breakpoints of MICs
followed those recommend by the Clinical and Laboratory
Standards Institute for Pseudomonas aeruginosa and non-
Enterobacteriaceae.16
Definitions
Significant bacteremia was defined as having the growth of
C indologenes in one or more blood cultures as well as
clinically manifesting signs of systemic inflammatory
response syndrome. The manifestations of systemic
inflammatory response syndrome include: (1) body
Chryseobacterium indologenes infections 427temperature lower than 36C or greater than 38C; (2)
heart rate greater than 90 beats/min; (3) tachypnea with
greater than 20 breaths/min or an arterial partial pressure
of carbon dioxide less than 32 mmHg; and (4) white blood
cell count of less than 4000 cells/mm3 or greater than
12,000 cells/mm3; or the presence of greater than 10%
immature neutrophils (band forms). Sputum samples were
collected from hospitalized patients with the clinical
diagnosis of pneumonia, as evidenced by the presence of
fever, productive cough, purulent sputum, or new infiltra-
tions in chest X-ray when compared to previous films, which
were reviewed by a chest physiologist. Gram staining was
performed on all sputum samples, which all yielded Gram-
negative rods with more than 25 polymorphonuclear cells
and less than 10 epithelial cells in the low power field
(100) of light microscopy. No pathogens other than
C indologenes, which showed significant growth in semi-
quantitative cultures, were noted. Co-pathogens of
C indologenes pneumonia were defined as the pathogens in
sputum samples within 7 days before or after the isolation
of C indologenes.
Immunosuppressive therapy was defined as the use of
cytotoxic agents or corticosteroids (>30 mg prednisolone
daily or equivalent for 1 week). Polymicrobial bacteremia
was defined as the presence of bacteria or yeasts in addi-
tion to C indologenes in the blood culture. Prior exposure to
antibiotics was defined as enteral or parenteral use of
antibiotics for at least 3 days, within 1 week before the
isolation of C indologenes. Appropriate antibiotic therapy
was defined as the use of at least one intravenous antibiotic
within 72 hours of the infection onset to which the micro-
organism was susceptible to the antibiotics. Clinical
prescriptions of colistin, tigecycline, and daptomycin were
expressed as the total daily doses in 3 months per 1000
patient-days (DDD/1000PD). Mortality due to C indologenes
bacteremia was defined as death within 14 days of onset of
bacteremia with no other identified cause of death.
Statistical analysis
We analyzed the correlation between the consumption
colistin, tigecycline, or daptomycin, and the number of
patients with C indologenes bacteremia and pneumonia byFigure 1. The correlation between colistin, tigecycline, and d
indologenes infections. Consumption of colistin, tigecycline, and da
days (DDDs/1000 PDs, right y-axis). Prevalence rate is calculated amultiple linear regression method. We analyzed the
differences between bacteremic and pneumonic patients,
with or without appropriate antibiotics using the Pearson
chi-square or Fisher’s exact test for dichotomous variables,
and t-test for continuous variables. A significant p value
was defined as less than 0.05.
Results
After the exclusion of 70 sputum isolates and 10 bacteremic
isolates, there were 215 C indologenes isolatesdincluding
138 from sputum of 91 patients, 39 from bloodstream of 22
patients, and 38 from other samples of 38 patient-
sdavailable for the study. The correlation between
colistin, tigecycline, or daptomycin consumption and the
prevalence of C indologenes infections is shown in Fig. 1.
The incidence of C indologenes increased gradually after
2006 (P < 0.0001). The isolate numbers of C indologenes
were correlated to increasing consumption of colistin
(pZ 0.018) or tigecycline (pZ 0.049), but not daptomycin
(p Z 0.051). The pulse field-gel electrophoresis profiles of
bacteremic C indologenes isolates, demonstrated in Fig. 2,
showed no cluster among C indologenes bacteremic
isolates.
As shown in Table 1, there was no apparent statistical
difference among patients with bacteremia and pneu-
monia, in terms of age, length of hospital stay, prior
exposure antibiotics, and disease severity [evaluated by
Acute Physiology and Chronic Health Evaluation (APACHE) II
score]. The only significant factor was male gender which
was more common in those with pneumonia than bacter-
emia (64.8% vs. 40.9%, p Z 0.040). Patients with C indo-
logenes bacteremia had more prior stroke (45.5% vs. 23.1%,
p Z 0.035) and underlying malignancy (50.0% vs. 23.1%,
p Z 0.012) than those with C indologenes pneumonia.
Other factors, such as ventilator-dependent status, prior
corticosteroid exposure, chronic kidney disease, diabetes
mellitus, and liver cirrhosis, were not different among the
two groups.
Only two (9.1%) patients with C indologenes bacteremia
and 19 (20.9%) patients with C indologenes pneumonia were
younger than 65 years. In patients with C indologenes
bacteremia, there was no documented infectiveaptomycin consumption and prevalence of Chryseobacterium
ptomycin is shown, defined as daily dose (DDDs)/1000 patient-
s patients’ number/100,000 patient-days (left, y-axis).
Figure 2. Pulse field-gel electrophoresis (PFGE) profile of
bacteremic Chryseobacterium indologenes isolates.
428 F.-L. Chen et al.endocarditis or neutropenia. Three (13.6%) patients with
C indologenes bacteremia were thought to have
community-acquired infection because the onset of
bacteremia occurred less than 48 hours after admission and
these patients had no recent hospitalization or visits to the
emergency department in the past year. Eighteen (81.8%)Table 1 Demographic data and clinical manifestations of pa
pneumonia
Variables Bacteremia
Age (y) 78.8  12.
Hospitalization duration (d) 54.6  53.
APACHE II score 24.4  11.
Male gender 9 (40.9)
Underlying diseases
Chronic obstructive pulmonary disease 7 (31.8)
Hypertensive cardiovascular disease 16 (72.7)
Arrhythmia 5 (22.7)
Congestive heart failure 4 (18.2)
Old stroke 10 (45.5)
Chronic kidney diseasea 10 (45.5)
Liver cirrhosis 2 (9.1)
Malignancy 11 (50.0)
Diabetes mellitus 4 (18.2)
Tracheostomy 6 (27.3)
Ventilator use 14 (63.6)
Corticosteroid 11 (50.0)
Previous antibiotic exposure within 7 d
Quinolone 6 (27.3)
Broad-spectrum cephalosporin 9 (40.9)
Piperacillin/tazobactam 5 (22.7)
Carbapenem 6 (27.3)
Tigecycline 2 (9.1)
Colistin 1 (4.5)
Clinical outcome
14-d mortality 8 (36.4)
30-d mortality 11 (50.0)
In-hospital mortality 14 (63.6)
Data are expressed as case numbers (%) or means  standard deviati
APACHE Z acute physiology and chronic health evaluation.
a Include patients depending on renal replacement therapy.of 22 patients with C indologenes bacteremia had
indwelling CVC and six had CVC-related bloodstream
infections, and one had concurrent bacteremia due to
methicillin-resistant Staphylococcus epidermidis, which
was also isolated from the CVC tip. In C indologenes
bacteremic patients, one had concurrent candidemia, one
had Pseudomonas bacteremia, and three had Enterococcus
faecalis bacteremia. In patients with C indologenes pneu-
monia, there was no pleural empyema.
The common co-pathogens (Fig. 3) were Acinetobacter
baumannii (36 patients; carbapenem-resistant: 22 [61.1%])
and P aeruginosa (23 patients; carbapenem-resistant: 10
[43.5%]). The results of in vitro susceptibility tests of 16
antimicrobial agents are shown in Tables 2 and 3. TMP-SMZ
was the most active agent, followed by cefperazone-
sulbactam. A total of six strains of C indologenes isolated
from wound and cerebrospinal fluid were all susceptible
(100%) to TMP-SMZ. However, only two wound isolates were
susceptible to cefoperazone-sulbactam, and only one
wound isolate was susceptible to ciprofloxacin and
levofloxacin.
The mortality rates of patients with bacteremia or
pneumonia, with or without appropriate antibioticstients with Chryseobacterium indologenes bacteremia and
, n Z 22 Pneumonia, n Z 91 p
6 74.8  16.4 0.214
6 70.5  110.5 0.332
5 21.2  8.40 0.178
59 (64.8) 0.040
19 (20.9) 0.274
54 (59.3) 0.246
14 (15.4) 0.295
17 (18.7) 0.613
21 (23.1) 0.035
27 (29.7) 0.157
2 (2.2) 0.170
21 (23.1) 0.012
33 (36.3) 0.105
35 (38.5) 0.327
49 (53.8) 0.407
34 (37.4) 0.277
39 (42.9) 0.180
35 (38.5) 0.833
14 (15.4) 0.409
45 (49.5) 0.061
13 (14.3) 0.405
9 (9.9) 0.381
19 (20.9) 0.126
29 (31.9) 0.110
32 (35.2) 0.015
ons.
Figure 3. Concurrent pneumonic pathogens among patients
with Chryseobacterium indologenes pneumonia.
CR Z carbapenem-resistant; ESBL Z extended-spectrum b-
lactamases.
Chryseobacterium indologenes infections 429treatment, are shown in Table 4. All pneumonic patients
received appropriate antibiotics therapy according to the
susceptibility for coexisting pathogens, such as A bau-
mannii, P aeruginosa, E coli, K pneumoniae and methicillin-
resistant S aureus. Those patients with C indologenes
bacteremia had a higher in-hospital mortality rate than
those with C indologenes pneumonia (63.6% vs. 35.2%,
p Z 0.015) or urinary tract infection (63.6% vs. 25.0%,
PZ 0.012). Even the APACHE II scores were similar in these
three groups. Of 22 patients with C indologenes bacter-
emia, eight died within 14 days after onset of bacteremia.Discussion
As stated previously, C indologenes is ubiquitous in nature
and is found in soil, plants, food products, and waterTable 2 In vitro susceptibility of 39 Chryseobacterium indologe
Drugs MIC (mg/mL)
Range MIC50
Cefotaxime 1 to >32 >32
Ceftazidime 1 to >16 >16
Cefepime 2 to >16 >16
Piperacillin-tazobactam 4/4 to >64/4 >64/4
Aztreonam >16 >16
Imipenem 1 to >8 >8
Meropenem 1 to >8 >8
Gentamicin 2 to >8 >8
Amikacin 8 to >32 >32
Ciprofloxacin 0.5 to >2 >2
Levofloxacin 1 to >8 8
Chloramphenicol 4 to >16 >16
TMP-SMZ 0.5/9.5 to >2/38 0.5/9.
Colistin >2 >2
Tigecyclinea 0.125 to 12 2
Cefoperazone-sulbactamb
MIC Z minimal inhibitory concentration; TMP-SMZ Z trimethoprim-su
a Susceptibility test by E-test; only 27 strains were available for an
b Susceptibility test by diffusion disk.sources despite adequate chlorination. C indologenes is
frequently recovered from wet surfaces and water sources
in the hospital environment. In 1993, Bonten et al3 first
isolated a strain of C indologenes from a tracheal aspirate
in a patient with ventilator-associated pneumonia. In 1996,
Hsueh et al1 found increasing incidence of healthcare-
associated infection due to Chryseobacterium species
other than C meningosepticum (Elizabethkingia meningo-
septica). In our study, we introduced colistin and tigecy-
cline into clinical use at this medical center in August 2006.
There was only one patient with C indologenes bacteremia
before August 1, 2006. Thereafter, the prevalence of
C indologenes greatly increased. After 2006, the numbers
of patients with isolated C indologenes infection correlated
with the increased consumption of colistin and tigecycline.
To our knowledge, this study is the first to describe
a correlation between C indologenes infection and the
consumption of colistin and tigecycline.
Chryseobacterium species are known to exhibit resis-
tance to aminoglycosides, tetracyclines, chloramphenicol,
erythromycin, clindamycin, and teicoplanin.1,17,18 Most
Chryseobacterium isolates are also resistant to colistin.19
C indologenes can produce several kinds of b-lact-
amase.11e15 It is possible that C indologenes may poten-
tially survive well in the environment, if there is frequent
exposure to broad-spectrum antibiotics, such as third- or
fourth-generation cephalosporins and carbapenems.
Increased use of broad-spectrum antibiotics, such as
colistin and tigecycline, especially aerosol colistin therapy,
may cause collateral damage and increase healthcare-
associated C indologenes infections.8,20
Nosocomial pneumonia and catheter-related bacteremia
accounted for most cases of C indologenes infections.1,21,22
In this study, which included 22 cases of bacteremia, 91 of
pneumonia, and 38 of other infections, all but three were
healthcare-associated infections. Accordingly, 18 of 22nes isolates from bloodstream
Susceptibility
breakpoint (mg/mL)
Susceptible (%)
MIC90
>32 8 2.6
>16 8 7.7
>16 8 7.7
>64/4 16/4 25.6
>16 8 0.0
>8 4 7.7
>8 4 7.7
>8 4 0.0
>32 16 0.0
>2 1 41.0
>8 2 41.0
>16 8 5.1
5 1/19 2/38 94.9
>2 1 0.0
12 2b 51.9
59.0
lfamethoxazole.
alysis.
Table 3 Susceptibility of 138 Chryseobacterium indologenes isolates from sputum in patients with pneumonia
Drugs MIC (mg/mL) Susceptibility
breakpoint (mg/mL)
Susceptible (%)
Range MIC50 MIC90
Cefotaxime 1 to >32 >32 >32 8 2.2
Ceftazidime 1 to >16 >16 >16 8 2.2
Cefepime 2 to >16 >16 >16 8 2.2
Piperacillin-tazobactam 4/4 to >64/4 >64/4 >64/4 16/4 30.5
Aztreonam >16 >16 >16 8 0.7
Imipenem 1 to >8 >8 >8 4 2.9
Meropenem 1 to >8 >8 >8 4 8.7
Gentamicin 2 to >8 >8 >8 4 0.0
Amikacin 8 to >32 >32 >32 16 0.0
Ciprofloxacin 0.5 to >2 >2 >2 1 29.0
Levofloxacin 1 to >8 8 >8 2 32.6
Chloramphenicol 4 to >16 >16 >16 8 9.4
TMP-SMZ 0.5/9.5 to >2/38 0.5/9.5 1/19 2/38 85.5
Colistin >2 >2 >2 1 0.0
Tigecyclinea 39.1
Cefoperazone-sulbactama 44.9
MIC Z minimal inhibitory concentration; TMP-SMZ Z trimethoprim-sulfamethoxazole.
a Susceptibility test by diffusion disk.
430 F.-L. Chen et al.cases of C indologenes bacteremia had CVC (data not
shown). Those findings are compatible with the published
data,1,21,22 suggesting that indwelling devices are frequent
causes of C indologenes bloodstream infection.7 The
production of biofilm on indwelling devices and protease
activity may play an important role in the virulence of
invasive C indologenes infections.23
Effective empirical treatment for C indologenes infec-
tions remains uncertain due to limited data in the litera-
ture. In an earlier study conducted by Hsueh et al1 in 1996,
all C indologenes isolates from the bloodstream were
uniformly susceptible to piperacillin, and 92% isolates were
susceptible to cefoperazone, ceftazidime, and minocy-
cline. Susceptibility to TMP-SMZ, ofloxacin, and cipro-
floxacin was variable.1 The isolates were consistently
resistant to other b-lactam antibiotics, including aztreonam
and imipenem, aminoglycosides, erythromycin, clindamy-
cin, or teicoplanin.1 In 2004, Kirby et al10 found that TMP-
SMZ, newer fluoroquinolones, ceftazidime, cefepime, and
piperacillin-tazobactam showed reasonable activity againstTable 4 Mortality rates in patients with Chrys-
eobacterium indologenes bacteremia or pneumonia with or
without appropriate antibiotics treatment
Case no. (%) p
Appropriate
antibiotics
Inappropriate
antibiotics
Bacteremia 9 13
14-d mortality 1 (11.1) 7 (53.9) 0.040
30-d mortality 3 (33.3) 8 (61.5) 0.193
In-hospital mortality 4 (44.4) 10 (76.9) 0.119
Pneumonia 41 50
14-d mortality 9 (22.0) 10 (20) 0.820
30-d mortality 13 (33.3) 16 (32) 0.976
In-hospital mortality 16 (39.0) 16 (32) 0.485more than 80% of the study isolates. In 2010, Lin et al7
suggested that only newer fluoroquinolones and TMP-SMZ
could possibly represent the most appropriate antimicro-
bial agents. In this study, we found that piperacillin-
tazobactam and newer fluoroquinolones are no longer
reliable due to decreased susceptibility. On the other hand,
TMP-SMZ and cefoperazone-sulbactam remained as reliable
antimicrobial agents to C indologenes, especially for
bloodstream infections. The usefulness of vancomycin
against Chryseobacterium infections has recently been
questioned,1,10,18,24 and vancomycin has not been included
in routine susceptibility testing. However, minocycline has
been shown to be active in vitro against C indologenes
isolates, with a susceptible rate of 92e100%.1,25
There are limited data on susceptibility to tigecycline of
C meningosepticum isolates.20 This is the first study to
evaluate the susceptibility of C indologenes to tigecycline,
and 52% of 27 bacteremic isolates were susceptible in vitro
to tigecycline, as determined by MICs (E-test). However,
tigecycline has not been recommended to treat blood-
stream infections. Among sputum isolates, the suscepti-
bility rate of tigecycline was higher (39.1%) than that of
fluoroquinolones, including levofloxacin (32.6%) and cipro-
floxacin (29.0%); thus tigecycline could not be recom-
mended for critically ill patients with presumed
C indologenes infections. Our study revealed, in compar-
ison with published data, an increased resistance rate of
C indologenes to previously potent antibiotics, including
fluoroquinolones, and we hypothesized that a resistant
pattern of C indologenes may evolve over time and vary
according to different trends of antibiotic usage.7
Hsueh et al in 199621 suggested that removal of the
indwelling device is not necessary for C indologenes
bacteremia. Lin et al7 in 2010 also found that C indologenes
can be eradicated with appropriate antibiotics without
removal of CVC. In this study, we found that there was
a significant benefit from using appropriate antibiotics for
Chryseobacterium indologenes infections 431cases of C indologenes bacteremia with or without removal
of CVC (PZ 0.04), although most patients died later due to
an underlying disease. However, no significant benefit of
appropriate antibiotics was noted for C indologenes pneu-
monia. The reason may be the clinical problem in dis-
tinguishing true pathogens from respiratory tract
colonization with the results of the growth of C indologenes
in respiratory secretions. In addition, many patients with
pneumonia may have concurrent pathogens other than C
indologenes. Based on these observations, it is likely that
co-infections or colonization by pathogens which secrete
carbapenem-hydrolyzing b-lactamase, such as C indolo-
genes, can cause higher treatment failure rate and higher
mortality rate.26
The present study has several limitations. First, this is
a retrospective study, and missing data may hide potential
risk factors which were not documented in records. Second,
the pathogenicity and virulence factors of C indologenes
remain unclear. Our patients with C indologenes isolated
from wound, cerebrospinal fluid, or ascites, were not
compared due to the limited number of cases. Third, the
introduction of an aggressive method for infection control,
such as care bundles for catheter-related bloodstream
infection or ventilator-associated pneumonia, in the
intensive care units since 2009 and the general wards since
2012, may influence the prevalence of C indologenes
infections. Lastly, the results of susceptibility testing varied
because of different testing methods. Disk diffusion
methods are especially unreliable, and broth microdilution
should be used, if possible.24 Although the E-test has been
suggested as a possible alternative for testing the suscep-
tibility of certain antibiotics,27 only strains from blood-
stream in this study were available and examined.
A well-designed prospective study to address these four
limitations may be necessary in the future to observe the
change of C indologenes infections after restricting the use
of tigecycline and colistin.
In conclusion, the present study demonstrated the
increasing prevalence of C indologenes infection since
colistin and tigecycline were introduced into clinical use.
C indologenes bacteremia resulted in a higher mortality
rate than pneumonia did, and the therapeutic benefit from
appropriate antibiotics was more evident in the former
infection entity. According to in vitro susceptibility study,
TMP-SMZ and cefoperazone-sulbactam may be potential
antimicrobial agents for C indologenes infections.Conflicts of interest
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